The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity-Reference-Cited by-同舟云学术

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity

Published:2020-02 Issue: Volume:470 Page:95-105
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Liu Chengming,Zheng Sufei,Jin Runsen,Wang Xinfeng,Wang Feng,Zang Ruochuan,Xu Haiyan,Lu Zhiliang,Huang Jianbing,Lei Yuanyuan,Mao Shuangshuang,Wang Yalong,Feng Xiaoli,Sun Nan,Wang Yan,He Jie^ORCID

Funder

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

CAMS Innovation Fund for Medical Sciences

National Key Basic Research Development Plan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference52 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA A Cancer J. Clin.,2018

2. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification;Travis;J. Thorac. Oncol.,2015

3. Precision diagnosis and treatment for advanced non-small-cell lung cancer;Reck;N. Engl. J. Med.,2017

4. Drugging RAS: know the enemy;Papke;Science (New York, N.Y.),2017

5. Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: lung Cancer Mutation Consortium (LCMC) database;Osta;J. Clin. Oncol.,2017

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy;Journal of Cancer Research and Clinical Oncology;2024-09-07

2. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma;International Immunopharmacology;2024-09

3. AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy;Frontiers in Immunology;2024-08-21

4. The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions;Cancers;2024-08-19

5. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08